Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
ATH
vs
S
S&P/ASX 300
ATH
Over the past 12 months, ATH has underperformed S&P/ASX 300, delivering a return of -31% compared to S&P/ASX 300's 4% drop.
Stocks Performance
ATH vs S&P/ASX 300
Performance Gap
ATH vs S&P/ASX 300
Performance By Year
ATH vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alterity Therapeutics Ltd
Glance View
Alterity Therapeutics is a clinical-stage biotechnology company that develops drug candidates for neurodegenerative diseases, especially disorders tied to abnormal iron handling and nerve cell damage. Its work is centered on finding treatments for conditions such as Parkinson’s-related syndromes and related brain diseases that currently have few effective options. The company does not sell a broad portfolio of approved medicines; it is mainly building and testing its own pipeline of experimental therapies. The company’s customers are not ordinary consumers. In the near term, it works with researchers, clinical trial sites, regulators, and sometimes partners that help fund or support development. If a candidate medicine succeeds, the end customers would be hospitals, doctors, patients, and health systems that use the approved treatment. Alterity makes money mainly through research funding, collaboration or licensing arrangements, and any future drug sales if one of its programs reaches the market. What makes Alterity’s business different is that it sits at the very early, high-risk end of the drug chain. It is not a large drug maker with many marketed products; it is a research company trying to turn lab science into a medicine for a hard-to-treat neurological disease area. That means its value depends heavily on the progress of its clinical programs and on whether larger pharmaceutical or healthcare partners see enough promise to support development.